Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphoma × elotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 46 Recurrence 8 Neoplasms, Plasma Cell 3 Smoldering Multiple Myeloma 2 Primary Myelofibrosis 1 Polycythemia Vera 1 Neoplasms 1 Lymphoma 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 402 Rituximab 358 Etoposide 204 Vincristine 192 Filgrastim 182 Doxorubicin 180 Prednisone 156 Radiotherapy 144 Cytarabine 144 fludarabine phosphate 129 Methotrexate 120 Melphalan 120 Peripheral Blood Stem Cell Transplantation 114 fludarabine 105 Busulfan 88 Dexamethasone 84 Carmustine 69 Granulocyte Colony-Stimulating Factor 64 Tacrolimus 62 Gemcitabine 61 Mycophenolic Acid 60 Whole-Body Irradiation 58 Bendamustine Hydrochloride 57 Antilymphocyte Serum 57 Cyclosporine 55 Ifosfamide 54 Lenalidomide 53 Bortezomib 52 sargramostim 43 Methylprednisolone 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡